Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro (tirzepatide) typically begins to reduce appetite within the first one to two weeks of starting treatment, though most people notice a meaningful difference in hunger and fullness cues during weeks two to four. The effect builds gradually as your body adjusts to the medicine — and for many, the clearest changes come after a dose increase. These are prescription-only medicines; a prescriber assesses whether treatment is clinically appropriate for you before anything is dispensed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The honest answer is: it varies more than most content suggests. Some people notice a quietening of hunger signals within the first few days, food feels less urgent, portions feel more filling. Others reach week three or four before they notice anything definitive. Neither pattern is a failure.
The mechanism helps explain the timing. Tirzepatide activates both GLP-1 and GIP receptors, slowing the rate at which food leaves your stomach and signalling satiety to the brain. That dual-receptor action is what makes Mounjaro the only medicine of its kind licensed for weight management in the UK, but the body needs time to respond to these new signals. The NHS tirzepatide patient information page describes how the medicine works, and the clinical picture it draws is one of progressive effect rather than a switch being flipped.
The SURMOUNT-1 trial (which involved 2,539 adults and ran for 72 weeks) recorded average body-weight reductions of around 20–21% at the 15 mg maintenance dose. That kind of result takes months, not days. The appetite changes that drive it accumulate in the same way. If you are at the beginning and not yet feeling much, you are almost certainly still in the adjustment window.
Generally, yes. The 2.5 mg starting dose exists primarily to help your digestive system adapt; its job is to reduce early nausea and GI discomfort, not to deliver peak appetite control. Many people find that hunger shifts more noticeably after moving to 5 mg, and again after each subsequent increase.
This is one of the more useful things to understand about how tirzepatide works over time: the appetite-suppressing effect is dose-dependent. Prescribers typically titrate in four-week steps, and the guidance from the NICE technology appraisal TA1026 for tirzepatide reflects that meaningful clinical effect is evaluated at the highest tolerated dose rather than the starting one. So if you are on 2.5 mg and waiting, the fuller picture may not arrive until you have been titrated upward.
That said, some people do experience notable appetite suppression at lower doses, and some find the GI side effects at higher doses harder to manage. The right dose for you is a clinical judgement. Worth knowing this when setting your expectations at week one.
A few things can blunt or delay the effect, and they are worth knowing about.
First, the timing in your weekly cycle matters. Tirzepatide is a once-weekly injection, and how quickly Mounjaro suppresses appetite tends to vary across the week, with effects strongest in the first few days after each dose and easing towards the end. If you are comparing your hunger on day six to day two, the difference can feel significant. That weekly rhythm settles for most people over time.
Second, stress, poor sleep and ultra-processed food patterns all work against the satiety signals the medicine is trying to strengthen. Tirzepatide is licensed alongside a reduced-calorie diet and increased activity, not as a replacement for either. Our full Mounjaro overview covers the lifestyle factors that support the medicine's effect.
Third, some people are metabolically slower to respond. If appetite suppression feels genuinely absent after several weeks at a stable dose, that conversation belongs with your prescriber. There is a separate page on what to do if Mounjaro appetite suppression is not working that goes into more detail.
We recognise that waiting for a medicine to do what you hoped it would do can be genuinely frustrating, particularly if you have spent years trying other approaches. That frustration is real and understandable. It is also, for most people, temporary.
For the majority of people, appetite suppression stabilises rather than disappears as they reach their maintenance dose. The acute GI effects (nausea especially) tend to ease, while the fuller-faster feeling persists. That is the intended pattern: the body tolerates the medicine better over time without losing the appetite-regulating benefit.
It is also worth knowing that coming off tirzepatide reverses this process. Appetite typically returns towards baseline over weeks, which is why the question of how to stop Mounjaro without gaining weight deserves careful planning with your prescriber rather than an abrupt stop.
If you are weighing up whether tirzepatide is the right route, understanding the broader timeline for when Mounjaro takes effect across different outcomes (not just appetite) may help. And if you are curious about what the treatment options currently available look like side by side, that is a reasonable place to start before a consultation.
Tirzepatide is a prescription-only medicine. A GPhC-registered prescriber at a regulated pharmacy reviews your clinical information before treatment can be prescribed. If you would like to find out whether you are eligible, you can start a free consultation with our clinical team, reviewed the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.